Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.43 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.39 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25344264 | 0.84 | TYMP (0.48) | — | |
| SCHEMBL10479252 | 0.82 | LMNA (0.44) | GRIA1GRIA2GRIA4GRIK5UPP1 | |
| SCHEMBL7834551 | 0.81 | EGFR (0.43) | UPP1DUTEGFRIGF1RSRC | |
| SCHEMBL7831021 | 0.80 | UPP1 (0.51) | UPP1EGFRIGF1RSRCFLT4 | |
| SCHEMBL9596714 | 0.80 | DUT (0.63) | GRIA1GRIA2GRIA4GRIK5UPP1 | |
| SCHEMBL6719621 | 0.79 | DGAT1 (0.42) | UPP1DUTEGFRIGF1RSRC | |
| SCHEMBL128471 | 0.78 | EGFR (0.34) | DUTEGFRIGF1RSRCFLT4 | |
| SCHEMBL19711624 | 0.76 | GRIA1 (0.54) | GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL10479219 | 0.74 | LMNA (0.42) | GRIA1GRIA2GRIA4GRIK5UPP1 | |
| SCHEMBL31564640 | 0.74 | DGAT1 (0.36) | EGFRIGF1RSRCFLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-01 | — | — | US | disclosed |
| EP-4472627-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118922185-A | N3-substituted uracil compounds as TRPA1 inhibitors | D·E·萧尔研究有限责任公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| US-6673804-B1 | PREVENTING OR TREATING ARTHRITIS (PARTICULARLY OSTEOARTHRITIS) OR INHIBITING METASTASIS, INVASION OR GROWTH OF CANCER (PARTICULARLY BREAST CANCER) | SANKYO COMPANY, LIMITED (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1069110-A1 | SULFONAMIDE DERIVATIVES | Sankyo Company Limited (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, SLC28A1 | GRIA1 975/4885GRIA2 1224/4885GRIA4 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.